当前位置： SCI文献检索 > Clinical Colorectal Cancer期刊下所有文献 > Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

Abstract：

BACKGROUND:Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-related genes affect the NLR remain unclear. PATIENTS AND METHODS:In 77 patients with KRAS exon2 wild-type mCRC from prospective trials of first-line chemotherapy with cetuximab, expression levels of 354 immune-related genes were measured in tissue samples obtained from all patients by the HTG EdgeSeq Oncology Biomarker Panel. The association between the NLR and clinical outcomes was evaluated using the Spearman rank correlation coefficient. In addition, 2-sample t tests were performed to investigate which genes among the top 100 genes associated with survival had significantly different expression levels between the NLR-low and NLR-high groups among all measured genes. RESULTS:NLR data were available for 71 patients. The NLR was associated with progression-free survival and overall survival (r = -0.24; P = .040 and r = -0.29; P = .010, respectively). When stratified by the median value of the NLR, the Kaplan-Meier curve of NLR-low versus NLR-high differed significantly for both progression-free survival (median, 11.8 vs. 9.1 months; P = .036) and overall survival (median, 42.8 vs. 26.7 months; P = .029). The 2-sample t test revealed that the expression levels of the LYZ, TYMP, and CD68 genes differed significantly between the NLR-low and NLR-high groups (t test P-value < .005; false discovery rate P-value < .15). CONCLUSION:NLR is significantly associated with survival in patients with mCRC treated with first-line chemotherapy with cetuximab. Genes encoding for activities on macrophages may affect the NLR.

journal_name

Clin Colorectal Cancer

journal_title

Clinical colorectal cancer

authors

Sunakawa Y,Yang D,Cao S,Zhang W,Moran M,Astrow SH,Hsiang J,Stephens C,Tsuji A,Takahashi T,Tanioka H,Negoro Y,Takagane A,Tani S,Yamaguchi T,Eto T,Fujii M,Ichikawa W,Lenz HJ

doi

10.1016/j.clcc.2018.08.002

subject

Has Abstract

pub_date

2018-12-01 00:00:00

pages

e741-e749

issue

4

eissn

1533-0028

issn

1938-0674

pii

S1533-0028(18)30353-0

journal_volume

17

pub_type

杂志文章

相关文献

Clinical Colorectal Cancer文献大全
  • Is levoleucovorin an alternative to racemic leucovorin? A literature review.

    abstract：PURPOSE:Our purpose is to perform a comprehensive literature review of the use of levoleucovorin in gastrointestinal malignancies and to assess whether levoleucovorin is a reasonable alternative to racemic leucovorin. DESIGN:This is an extensive literature review of levoleucovorin use in patients with gastrointestinal...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2009.n.034

    authors： Kovoor PA,Karim SM,Marshall JL

    更新日期：2009-10-01 00:00:00

  • Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

    abstract：:The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has ushered in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). The anti-EGFR monoclonal antibodies cetuximab and panitu...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2015.05.006

    authors： Lee MS,Kopetz S

    更新日期：2015-12-01 00:00:00

  • Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.

    abstract：BACKGROUND:ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab. We present long-term clinical results of trastuzumab and lapatinib (HERACLES-A...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.06.009

    authors： Tosi F,Sartore-Bianchi A,Lonardi S,Amatu A,Leone F,Ghezzi S,Martino C,Bencardino K,Bonazzina E,Bergamo F,Fenocchio E,Martinelli E,Troiani T,Siravegna G,Mauri G,Torri V,Marrapese G,Valtorta E,Cassingena A,Cappello G

    更新日期：2020-12-01 00:00:00

  • Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System.

    abstract：BACKGROUND:Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. MATERIALS AND METHODS:The Harris Health System (HHS) is an integrated health delivery network that provides medical car...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2019.09.002

    authors： Lau-Min K,Prakash P,Jo E,Thrift AP,Hilsenbeck S,Musher BL

    更新日期：2020-06-01 00:00:00

  • Therapeutic Evaluation of Biofeedback Therapy in the Treatment of Anterior Resection Syndrome After Sphincter-Saving Surgery for Rectal Cancer.

    abstract：BACKGROUND:Anterior resection syndrome (ARS) is common after sphincter-saving surgery for rectal cancer. It includes changes in the frequency and urgency of bowel movements and fecal incontinence. The therapeutic efficacy of biofeedback on ARS is unclear. We sought to evaluate the effectiveness of biofeedback therapy i...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2015.11.002

    authors： Liang Z,Ding W,Chen W,Wang Z,Du P,Cui L

    更新日期：2016-09-01 00:00:00

  • Intussusception in colorectal cancer.

    abstract：:Adult intussusception is a rare occurrence and, unlike in childhood, is usually associated with an underlying tumor. Although computed tomography (CT) imaging can identify an intussusception and point toward a cause, diagnosis is challenging if it is only intermittent. When an intussusception presents in the context o...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2008.n.028

    authors： Chand M,Bradford L,Nash GF

    更新日期：2008-05-01 00:00:00

  • Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer.

    abstract：BACKGROUND:With improved survival and longer duration of treatment, clinicians managing metastatic colorectal cancer (mCRC) increasingly consider intermittent (IC) or maintenance chemotherapy (MC), but the effect of these treatment modifications on real-world outcomes is unclear. PATIENTS AND METHODS:Using a populatio...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2017.10.011

    authors： Loree JM,Tan SK,Lafond LM,Speers CH,Kennecke HF,Cheung WY

    更新日期：2018-03-01 00:00:00

  • Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

    abstract：PURPOSE:The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations. Capecitabine is also at least as effective as bolus 5-FU/LV i...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/ccc.2005.n.021

    authors： Twelves CJ,Butts CA,Cassidy J,Conroy T,Braud Fd,Diaz-Rubio E,Tabernero JM,Schoffski P,Figer A,Brunet R,Grossmann J,Sobrero AF,Van Cutsem EJ

    更新日期：2005-07-01 00:00:00

  • Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.

    abstract：:To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current trea...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2015.10.002

    authors： Goldstein DA,Zeichner SB,Bartnik CM,Neustadter E,Flowers CR

    更新日期：2016-03-01 00:00:00

  • The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.

    abstract：BACKGROUND:Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type (WT) KRAS tumors. Although skin toxicities are the most common adverse events associated with EGFR in...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clcc.2011.06.004

    authors： Mitchell EP,Piperdi B,Lacouture ME,Shearer H,Iannotti N,Pillai MV,Xu F,Yassine M

    更新日期：2011-12-01 00:00:00

  • Multidisciplinary perspective on the management of appendiceal adenocarcinoma: case review of 10 patients from a university hospital and current considerations.

    abstract：BACKGROUND:Adenocarcinoma of the vermiform appendix is rare. It constitutes less than 0.5% of all gastrointestinal malignancies. Pathologically, appendiceal neoplasms are categorized into various subtypes depending on cell lineage. PATIENTS AND METHODS:We considered a case series of appendiceal invasive adenocarcinoma...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2014.11.003

    authors： Bunni J,Arnold D,Shelley-Fraser G,Shabbir J

    更新日期：2015-03-01 00:00:00

  • Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions.

    abstract：:The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added to chemotherapy does not seem to be bet...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2010.n.039

    authors： Chibaudel B,Tournigand C,André T,Larsen AK,de Gramont A

    更新日期：2010-12-01 00:00:00

  • Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.

    abstract：:Despite an armamentarium that is wide in range, scope of action, and target, chemotherapy has limited success in colorectal cancer (CRC). Novel approaches are needed to overcome tumor barriers to chemotherapy that includes an abnormal tumor vasculature constituting a poor drug delivery system. We have previously shown...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2009.n.025

    authors： Bhattacharya A,Tóth K,Sen A,Seshadri M,Cao S,Durrani FA,Faber E,Repasky EA,Rustum YM

    更新日期：2009-07-01 00:00:00

  • The Role of the Gut Microbiome in Colorectal Cancer: Where Are We? Where Are We Going?

    abstract：:Microbiome (microbiota) is a community of all microorganisms inhabiting a specific site of the body, including pathogens, which distinguishes it from the physiological microflora. Intestinal dysbiosis plays a key role in the development of colorectal cancer. In the process of carcinogenesis, inflammation, immune respo...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2019.07.006

    authors： Wieczorska K,Stolarek M,Stec R

    更新日期：2020-03-01 00:00:00

  • Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.

    abstract：:Significant advances have been made with respect to our understanding of the critical role of agents targeting angiogenic pathways in the treatment of metastatic colorectal cancer (mCRC). The approval of 3 agents that target angiogenic signaling, bevacizumab, ziv-aflibercept, and regorafenib, provides strong evidence ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2014.02.001

    authors： Lee JJ,Chu E

    更新日期：2014-09-01 00:00:00

  • Interval colorectal cancer after colonoscopy.

    abstract：BACKGROUND:As more patients are screened for colorectal cancer a small but significant number of interval cancers develop after colonoscopy for colorectal cancer screening. MATERIALS AND METHODS:We reviewed records of 75,314 adult patients who underwent colonoscopy for screening or diagnostic purposes between 1998 and...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2014.11.001

    authors： Richter JM,Campbell EJ,Chung DC

    更新日期：2015-03-01 00:00:00

  • First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.

    abstract：BACKGROUND:Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. PATIENTS AND METHODS:Using a modified Simon accelerated titration design, adults with...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.08.003

    authors： Winer A,Denlinger CS,Vijayvergia N,Cohen SJ,Astaturov I,Dotan E,Gallant JN,Wang EW,Kunkel M,Lim B,Harvey HA,Sivik J,Korzekwa K,Ruth K,White K,Cooper HS,Ross EA,Zhou L,El-Deiry WS

    更新日期：2020-08-19 00:00:00

  • Adjuvant radiation therapy of patients with rectal cancer.

    abstract：:The standard in rectal cancer has been to add adjuvant radiation therapy to surgery in patients with stage II and III disease. Total mesorectal excision has led to lower local recurrence rates, and, if properly performed, may make adjuvant radiation unnecessary for certain stage II and III patients, such as T3 N0 pati...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2003.n.002

    authors： Bechtel J,Tepper J

    更新日期：2003-02-01 00:00:00

  • Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.

    abstract：INTRODUCTION:In studies of colorectal cancer, the elderly have been frequently underrepresented because comorbid conditions and functional status often lead to study exclusion. For elderly patients with an indication for neoadjuvant chemoradiotherapy (nCRT), physicians usually decide using clinical factors whether nCRT...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.03.004

    authors： Jacobs L,van der Vlies E,Ten Bokkel Huinink D,Bloemendal H,Intven M,Smits AB,Weusten BLAM,Siersema PD,van Lelyveld N,Los M

    更新日期：2018-09-01 00:00:00

  • Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

    abstract：BACKGROUND:Individually, oxaliplatin and irinotecan have substantial activity in metastatic colorectal cancer (CRC) in combination with 5-fluorouracil/leucovorin. A combination regimen using all 4 agents could potentially increase response rates in CRC. PATIENTS AND METHODS:A multicenter phase II trial of oxaliplatin ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/CCC.2007.n.017

    authors： McWilliams RR,Goetz MP,Morlan BW,Salim M,Rowland KM,Krook JE,Ames MM,Erlichman C

    更新日期：2007-05-01 00:00:00

  • A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.

    abstract：:This phase II study was designed to characterize the clinical activity of ISIS 3521 in patients with metastatic colorectal cancer (CRC). Sixteen patients with pretreated or refractory CRC were treated with ISIS 3521. Eleven patients were given a dose of 2.0 mg/kg per day, and 5 patients received 3.0 mg/kg per day give...

    journal_title：Clinical colorectal cancer

    pub_type： 临床试验,杂志文章

    doi：10.3816/ccc.2004.n.026

    authors： Marshall JL,Eisenberg SG,Johnson MD,Hanfelt J,Dorr FA,El-Ashry D,Oberst M,Fuxman Y,Holmlund J,Malik S

    更新日期：2004-11-01 00:00:00

  • Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases.

    abstract：:The development of brain metastases originating from colorectal cancer (CRC) is an infrequent phenomenon occurring in < 5% of patients. Yet, it is feasible that physicians will be diagnosing more patients with brain metastases because of the prolonged survival in our current patient population. The anti-angiogenic age...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2008.n.010

    authors： Bhaskara A,Eng C

    更新日期：2008-01-01 00:00:00

  • Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.

    abstract：BACKGROUND:Few patients with metastatic colorectal cancer (mCRC) are candidates for resection of their hepatic disease. Yttrium-90 ((90)Y) radioembolization has promise in the treatment of unresectable mCRC. We conducted a retrospective study to assess the efficacy in patients with refractory mCRC who underwent (90)Y r...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2011.12.002

    authors： Martin LK,Cucci A,Wei L,Rose J,Blazer M,Schmidt C,Khabiri H,Bloomston M,Bekaii-Saab T

    更新日期：2012-09-01 00:00:00

  • Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age.

    abstract：BACKGROUND:Screening protocols for colorectal cancer are broadly recommended and effective in reducing mortality. However, populations from different age groups can harbor distinct pathologic and molecular profiles that can also be influenced by screening and polyp resection, especially in older ages. PATIENTS AND MET...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.06.004

    authors： Pereira AAL,Fernandes GDS,Braga GTP,Marchetti KR,Mascarenhas CDC,Gumz B,Crosara M,Dib L,Girardi D,Barrichello A,Seidler H

    更新日期：2020-12-01 00:00:00

  • Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study.

    abstract：INTRODUCTION:Hepatic arterial infusion chemotherapy (HAIC) is a treatment used for liver metastases (LM) of colorectal cancer (CRC). Because of its technical conditions, it has been used in only a few experienced centers in France. Our aim was to evaluate its feasibility, efficacy and tolerance in 4 centers. METHODS:C...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clcc.2017.03.003

    authors： Lim A,Le Sourd S,Senellart H,Luet D,Douane F,Perret C,Bouvier A,Métairie S,Cauchin E,Rougier P,Matysiak-Budnik T,Touchefeu Y

    更新日期：2017-12-01 00:00:00

  • A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.

    abstract：INTRODUCTION:The aim of this study was to evaluate the efficacy and safety of maintenance therapy with axitinib versus placebo following induction therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In this double-blinded, phase II trial, patients with mCRC who had not progressed after 6...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clcc.2018.02.004

    authors： Grávalos C,Carrato A,Tobeña M,Rodriguez-Garrote M,Soler G,Vieitez JM,Robles L,Valladares-Ayerbes M,Polo E,Limón ML,Safont MJ,Martínez de Castro E,García-Alfonso P,Aranda E,Spanish Cooperative Group for the Treatment of Digest

    更新日期：2018-06-01 00:00:00

  • Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis.

    abstract：BACKGROUND:The prognostic value of tumor sidedness in metastatic colorectal cancer (CRC) has been established, but its impact on nonmetastatic disease remains unclear. Our study aimed to explore the prognostic effect of tumor sidedness by subgroup survival analyses, according to histology and tumor grade in stage I-IV ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.10.005

    authors： Li Y,Feng Y,Dai W,Li Q,Cai S,Peng J

    更新日期：2019-03-01 00:00:00

  • Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.

    abstract：BACKGROUND:New treatment modalities and a growing understanding of the complex genetic tumor landscape have improved the outcome of colorectal cancer (CRC) patients. Nonetheless, more individualized treatment regimens, taking individual tumor characteristics into account, have been recently postulated and prognostic bi...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.02.008

    authors： Semaan A,Uhl B,Branchi V,Lingohr P,Bootz F,Kristiansen G,Kalff JC,Matthaei H,Pantelis D,Dietrich D

    更新日期：2018-06-01 00:00:00

  • Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.

    abstract：:Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal cancer of teh gastrointestinal tract. They are characterized by the expression of KIT. Therapeutically, metastatic GISTs are effectively treated by imatinib, a tyrosine kinase inhibitor (TKI) with activity against KIT and platelet-derived growth f...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2006.s.005

    authors： von Mehren M

    更新日期：2006-11-01 00:00:00

  • Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.

    abstract：:Replacing infusional 5-fluorouracil (5-FU) leucovorin (LV) with oral capecitabine would be more convenient to patients, because it would lead to reduced hospital chair time and infusion-related toxicities. Previous trials with oral capecitabine-based regimens (other than XELOX [capecitabine/oxaliplatin]) have failed t...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2006.n.044

    authors： Tyagi P,Grothey A

    更新日期：2006-11-01 00:00:00